Fifty 1 Labs, Inc. Engages PCAOB Auditing Firm to Prepare for Uplist to OTCQB
Fifty 1 Labs (OTC:FITY) has engaged a PCAOB-registered auditing firm to conduct audits of its 2024 and 2025 financial statements, marking a crucial step toward uplisting to the OTCQB® Venture Market. This strategic move aims to enhance the company's market visibility and attract broader investor interest.
The Nevada-based holding company, focused on AI-driven drug repurposing and functional medicine, demonstrates its commitment to transparency and corporate governance through this initiative. Additionally, the company recently published a technical primer on transportability methods in oncology real-world evidence in the Journal of Comparative Effectiveness Research, highlighting its expertise in AI and oncology data analysis.
Fifty 1 Labs (OTC:FITY) ha affidato a una società di revisione registrata presso la PCAOB lo svolgimento delle verifiche dei bilanci 2024 e 2025, segnando un passo cruciale verso l’uplisting al OTCQB® Venture Market. Questa mossa strategica punta a aumentare la visibilità sul mercato e ad attrarre un interesse più ampio da parte degli investitori.
La holding con sede in Nevada, focalizzata sull’AI per il riposizionamento di farmaci e sulla medicina funzionale, dimostra il proprio impegno per trasparenza e buona governance tramite questa iniziativa. Inoltre, l’azienda ha recentemente pubblicato un primer tecnico sui metodi di trasportabilità nelle evidenze real-world in oncologia sul Journal of Comparative Effectiveness Research, evidenziando la sua expertise in IA e analisi di dati oncologici.
Fifty 1 Labs (OTC:FITY) ha contratado a una firma de auditoría registrada en la PCAOB para realizar las auditorías de sus estados financieros de 2024 y 2025, marcando un paso clave hacia la cotización en el OTCQB® Venture Market. Este movimiento estratégico busca fortalecer la visibilidad de la empresa en el mercado y atraer un interés más amplio de los inversionistas.
La empresa holding con sede en Nevada, centrada en la redistribución de fármacos impulsada por IA y en la medicina funcional, demuestra su compromiso con la transparencia y la gobernanza corporativa mediante esta iniciativa. Además, la compañía publicó recientemente un primer artículo técnico sobre métodos de transportabilidad en la evidencia del mundo real en oncología en el Journal of Comparative Effectiveness Research, destacando su experiencia en IA y análisis de datos oncológicos.
Fifty 1 Labs (OTC:FITY)가 PCAOB에 등록된 회계법인에 의뢰하여 2024년 및 2025년 재무제표에 대한 감사를 수행하도록 했으며, 이는 OTCQB® Venture Market으로의 상장 승격을 향한 중요한 단계입니다. 이 전략적 조치는 시장 내 가시성을 강화하고 더 넓은 투자자 관심을 유도하는 것을 목표로 합니다.
네바다주에 본사를 둔 지주회사는 AI 기반의 약물 재활용 및 기능의학에 중점을 두고 있으며, 이번 이니셔티브를 통해 투명성과 기업 거버넌스에 대한 약속을 입증합니다. 또한 이 회사는 최근 종양학 현장증거의 운송 가능성 방법에 관한 기술적 입문서를 Journal of Comparative Effectiveness Research에 발표하여 AI 및 종양 데이터 분석에 대한 전문성을 강조했습니다.
Fifty 1 Labs (OTC:FITY) a confié à un cabinet d’audit enregistré par le PCAOB l’audit de ses états financiers 2024 et 2025, marquant une étape clé vers l’entrée en bourse sur le OTCQB® Venture Market. Cette démarche stratégique vise à accroître la visibilité de l’entreprise sur le marché et à attirer un intérêt plus large des investisseurs.
La holding basée au Nevada, axée sur le repositionnement de médicaments guidé par l’IA et sur la médecine fonctionnelle, démontre son engagement envers la transparence et la gouvernance d’entreprise à travers cette initiative. De plus, l’entreprise a récemment publié un primer technique sur les méthodes de transportabilité dans les preuves du monde réel en oncologie dans le Journal of Comparative Effectiveness Research, mettant en avant son expertise en IA et en analyse de données oncologiques.
Fifty 1 Labs (OTC:FITY) hat eine von der PCAOB registrierte Prüfungsfirma beauftragt, die Abschlüsse für 2024 und 2025 zu prüfen, was einen wichtigen Schritt auf dem Weg zum Upgrade auf den OTCQB® Venture Market darstellt. Diese strategische Maßnahme zielt darauf ab, die Sichtbarkeit des Unternehmens am Markt zu erhöhen und das Interesse einer breiteren Investorenbasis zu wecken.
Das in Nevada ansässige Holding-Unternehmen, das sich auf KI-gesteuertes Drug Repositioning und Funktionsmedizin konzentriert, demonstriert sein Engagement für Transparenz und Corporate Governance durch diese Initiative. Zudem hat das Unternehmen kürzlich ein technisches Primer zu Transportabilitätsmethoden in der onkologischen Real-World-Evidence im Journal of Comparative Effectiveness Research veröffentlicht und damit seine Expertise in KI und Onkologie-Datenanalyse hervorgehoben.
Fifty 1 Labs (OTC:FITY) قد كلفت شركة تدقيق مسجّلة لدى PCAOB لإجراء تدقيق البيانات المالية لعامي 2024 و2025، وهو خطوة حاسمة نحو الإدراج في OTCQB® Venture Market. تهدف هذه الخطوة الاستراتيجية إلى تعزيز ظهور الشركة في السوق وجذب اهتمام مستثمرين أوسع.
الشركة القابضة المقيمة في نيفادا، والمختصة بإعادة توظيف الأدوية باستخدام الذكاء الاصطناعي والطب الوظيفي، تُظهر التزامها بالشفافية والحوكمة المؤسسية من خلال هذه المبادرة. بالإضافة إلى ذلك، نشرت الشركة مؤخرًا مقدمة تقنية حول أساليب قابلية النقل في أدلة الواقع الحقيقي في علم الأورام في مجلة Journal of Comparative Effectiveness Research، مع تسليط الضوء على خبرتها في الذكاء الاصطناعي وتحليل بيانات الأورام.
Fifty 1 Labs (OTC:FITY) 已委托一家经PCAOB注册的审计事务所，对其2024年和2025年的财务报表进行审计，这是向< b>OTCQB® Venture Market上市迈出的关键一步。这一战略举措旨在提升公司在市场上的知名度并吸引更广泛的投资者关注。
这家总部位于内华达州的控股公司，专注于基于人工智能的药物再定位和功能医学，通过这一举措展现其对透明度与企业治理的承诺。此外，该公司最近在《Journal of Comparative Effectiveness Research》上发表了一篇关于肿瘤学真实世界证据可迁移性方法的技术入门文章，凸显了其在人工智能和肿瘤数据分析方面的专业能力。
- Engagement of PCAOB auditor demonstrates commitment to transparency and governance standards
- Strategic preparation for OTCQB uplist could enhance stock visibility and liquidity
- Recent publication in peer-reviewed journal showcases company's AI and oncology expertise
- Current OTC listing indicates lower tier market status
- Audits for 2024-2025 suggest potential timeline delays before uplist completion
Fifty 1 Labs continues to advance its portfolio of biotech and wellness initiatives
VANCOUVER, British Columbia, Sept. 23, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 Labs, Inc, (OTC:FITY) a Nevada-based holding company revolutionizing health, wellness, and biotech through AI-driven drug repurposing and functional medicine, today announced that it has signed a letter of engagement with a Public Company Accounting Oversight Board (PCAOB) registered auditing firm. The engagement covers audits of the Company's 2024 and 2025 financial statements.
The completion of these audits represents a critical step in Fifty 1 Labs' plan to uplist its shares to the OTCQB® Venture Market, an established marketplace operated by OTC Markets Group. The OTCQB tier requires companies to meet strict reporting, financial, and governance standards, including maintaining audited financials.
"Our engagement with a PCAOB auditing firm demonstrates Fifty 1 Labs' commitment to transparency, compliance, and the highest standards of corporate governance," said Paul Arora, CEO of Fifty 1 Labs, Inc. "By undertaking two full years of audits, we are building the foundation for an uplist to OTCQB and strengthening shareholder confidence in our financial reporting as we execute on our mission to transform biotech and functional medicine."
The Company believes that an OTCQB listing will broaden its visibility within the investment community, attract institutional and retail investors, and enhance overall liquidity in its stock.
Fifty 1 Labs continues to advance its portfolio of biotech and wellness initiatives, leveraging artificial intelligence to accelerate drug repurposing and advance personalized approaches to health through functional medicine.
Fifty 1 Labs recently announced the publication of a landmark technical primer on "transportability" methods in oncology real-world evidence (RWE). Authored by CTO Alind Gupta and CEO Paul Arora, the primer, published in the Journal of Comparative Effectiveness Research (https://becarispublishing.com/doi/10.57264/cer-2025-0041) showcases the company's leadership at the intersection of advanced statistics, AI, and oncology data.
About Fifty1 AI Labs
Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: FITY), is revolutionizing drug discovery by leveraging AI to unlock new potential in proven medicines. By repurposing safe, off-patent compounds, we accelerate smarter therapies that improve lives, reduce costs, and create lasting value for patients, partners, and forward-thinking investors.
Contact:
Investor Relations
Fifty1 Labs, Inc.
ir@fifty1labs.com | (877) 505-5006
www.fifty1AIlabs.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding the potential impact, development, and timeline of AI-powered drug repurposing, the scalability of transportability frameworks, and the ability of Fifty1 AI Labs' platform to transform oncology and global health outcomes, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause the company's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the success and timing of partnerships and projects, the efficacy and safety of repurposed treatments, regulatory approvals, and the company's ability to successfully develop and commercialize its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, please refer to Fifty1 Labs, Inc.'s filings with the OTC Markets. The company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
FAQ
What is the significance of Fifty 1 Labs (FITY) engaging a PCAOB auditing firm?
When will Fifty 1 Labs (FITY) complete its PCAOB audits?
What are the benefits of Fifty 1 Labs uplisting to OTCQB?
What is Fifty 1 Labs' core business focus?
What recent scientific achievement has Fifty 1 Labs announced?
